Investors are always looking for stocks that are poised to beat at earnings season and Mersana Therapeutics, Inc. (NASDAQ:MRSN) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Mersana Therapeutics is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for MRSN in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 45 cents per share for MRSN, compared to a broader Zacks Consensus Estimate of a loss of 48 cents per share. This suggests that analysts have very recently bumped up their estimates for MRSN, giving the stock a Zacks Earnings ESP of +5.76% heading into earnings season.
Mersana Therapeutics, Inc. Price and EPS Surprise
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that MRSN has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for Mersana Therapeutics, and that a beat might be in the cards for the upcoming report.
Breaking News: Cryptocurrencies Now Bigger than Visa
The total market cap of all cryptos recently surpassed $700 billion – more than a 3,800% increase in the previous 12 months. They’re now bigger than Morgan Stanley (NYSE:MS), Goldman Sachs (NYSE:GS) and even Visa! The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved.
Zacks’ has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market.
Click here to access these stocks. >>
Mersana Therapeutics, Inc. (MRSN): Free Stock Analysis Report
Original post
Zacks Investment Research